Real-world evidence of survival outcomes in breast cancer subtypes after neoadjuvant chemotherapy in a Brazilian reference center.

Autor:	Antonini M; Mastology Department, Hospital do Servidor Público Estadual (HSPE-FMO), São Paulo, Brazil., Mattar A; Mastology Department, Women's Health Hospital, São Paulo, Brazil., Bauk Richter FG; Mastology Department, Women's Health Hospital, São Paulo, Brazil., Pannain GD; Mastology Department, Hospital do Servidor Público Estadual (HSPE-FMO), São Paulo, Brazil., Teixeira MD; Mastology Department, Women's Health Hospital, São Paulo, Brazil., Amorim AG; Mastology Department, Women's Health Hospital, São Paulo, Brazil., da Costa Pinheiro DJP; Mastology Department, Hospital do Servidor Público Estadual (HSPE-FMO), São Paulo, Brazil., Soares LR; Mastology Department, Hospital das Clínicas, Federal University of Goiás (UFG), Goiânia, Brazil., Cavalcante FP; Mastology Department, Hospital Geral de Fortaleza (HGF), Fortaleza, Brazil., Moreira Ramos MDN; Mastology Department, Women's Health Hospital, São Paulo, Brazil., Madeira M; Mastology Department, Faculdade Israelita de Ciências da Saúde Albert Einstein (FICSAE), São Paulo, Brazil., Zerwes F; Mastology Department, Medical School of PUC-RS, Porto Alegre, Brazil., Ferraro O; Mastology Department, Hospital do Servidor Público Estadual (HSPE-FMO), São Paulo, Brazil., Lopes RGC; Mastology Department, Hospital do Servidor Público Estadual (HSPE-FMO), São Paulo, Brazil., Gebrim LH; Mastology Department, Beneficiencia Portuguesa de São Paulo, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Chinese clinical oncology [Chin Clin Oncol] 2024 Oct; Vol. 13 (5), pp. 65. Date of Electronic Publication: 2024 Sep 23.
DOI:	10.21037/cco-24-54
Abstrakt:	Background: Neoadjuvant chemotherapy (NAC), traditionally used for locally advanced disease, is now applied for operable disease, particularly to treat aggressive breast cancer (BC). This study aimed to characterize the pathological complete response (pCR) and its relationship with overall survival (OS) and disease-free survival (DFS) among BC patients receiving NAC in a Brazilian public reference center, as well as the association between pCR and BC subtypes. Methods: A retrospective cohort study used a comprehensive BC database from a Brazilian women's health reference center, including patients diagnosed between 2011 and 2020 who underwent NAC. We collected demographic, cancer-specific, and treatment-related data, analyzing OS and DFS based on pCR status using the semiparametric Kaplan-Meier method, with the date of BC diagnosis as the starting point. Results: The study included 1,601 patients, with an average age of 49 years and a majority presenting stage IIIa disease (35%). Most had invasive nonspecial type (NST) BC (94%), and a significant portion (86.7%) exhibited a Ki-67 index <14. The overall pCR rate was 22.7%, with higher frequencies observed in the triple negative and luminal B subtypes. Patients who achieved pCR had significantly higher survival rates (89% alive vs. 61%, P<0.001) and better DFS (90% vs. 66%, P<0.001), except in the luminal A subtype, where pCR did not correlate with improved OS or DFS. Conclusions: These updated real-world data (RWD) from BC patients who underwent NAC in Brazil revealed a pCR rate of 22.7% in all cancer subtypes and stages. pCR was not associated with better outcomes in patients with luminal A, contrasting with other subtypes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu